Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice Regarding Revision of Financial Forecasts for FY2025
Presentation Material for information Meeting (Q2 YTD/FY2025)
Supplementary Documents (Q2 YTD/FY2025)
Financial Results (Q2 YTD/FY2025)
Astellas Pharma, Net Income Forecast for the Fiscal Year Revised Upward by 38%
Astellas Confirms Phase 2 GLEAM Trial Did Not Meet Primary Endpoint of Overall Survival in Patients with Metastatic Pancreatic Cancer
Astellas Receives Conditional Approval for IZERVAY in Japan
PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
Astellas Pharma, Apr-Jun (1Q) Net Income Increases by 82%
Supplementary Documents (Q1 YTD/FY2025)
[Summary]Financial Results (Q1 YTD/FY2025)
Presentation Material for Information Meeting (Q1 YTD/FY2025)
Corporate Governance Report
Sales of IZERVA (Preliminary Figures)
Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme and Performance-linked Stock Delivery Scheme for the Executives
Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme
Notice of Nominees for Directors
Presentation Material for Information Meeting (FY2024)
Supplementary Documents (FY2024)
Financial Results (FY2024)